Core Sales Growth
Aptar achieved core sales growth of 2% and adjusted EPS of $1.49 per share, a 6% increase over the prior year's quarter. Adjusted EPS grew by 15% for the first 9 months of the year.
Pharma Segment Performance
Pharma segment reported 12% core sales growth, driven by strong demand for proprietary drug delivery systems. Adjusted EBITDA margins were at the high end of the long-term target range.
Closure Segment Recovery
Closures segment returned to its core sales long-term target range with 4% growth and improved adjusted EBITDA margins of 17%, driven by increased demand and cost reduction efforts.
Significant Developments in Pharma
FDA approval for nasally delivered emergency medicine neffy and acquisition of SipNose's technology assets for intranasal delivery platforms.
Recognition and Innovations
Time named Aptar among World's Best Companies of 2024. Introduced multiple new products and received a contract from the U.S. government for ActivShield sterilization technology.